Valproic acid (VPA)

For research use only. Not for use in humans.

目录号:S3944 别名: 2-Propylvaleric Acid, Valproate 中文名称:丙戊酸

Valproic acid (VPA) Chemical Structure

CAS No. 99-66-1

Valproic acid (VPA, 2-Propylvaleric Acid, Valproate)是一种具有抗惊厥性质的脂肪酸,可用于治疗癫痫。它也是一种 histone deacetylase (HDAC) 抑制剂,正用于研究治疗HIV和各种癌症的方法。Valproic acid (VPA) 通过上调 BNIP3 诱导自噬和线粒体自噬,并通过上调 PGC-1α 来诱导线粒体的生物合成。Valproic acid (VPA) 可激活 Notch-1 信号传递。

规格 价格 库存 购买数量  
RMB 794.92 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Valproic acid (VPA)发表文献22篇:

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Valproic acid (VPA, 2-Propylvaleric Acid, Valproate)是一种具有抗惊厥性质的脂肪酸,可用于治疗癫痫。它也是一种 histone deacetylase (HDAC) 抑制剂,正用于研究治疗HIV和各种癌症的方法。Valproic acid (VPA) 通过上调 BNIP3 诱导自噬和线粒体自噬,并通过上调 PGC-1α 来诱导线粒体的生物合成。Valproic acid (VPA) 可激活 Notch-1 信号传递。
靶点
HDAC1 [1]
(Cell-free assay)
0.4 mM
体外研究

Valproic acid (VPA), like lithium, activates Wnt-dependent gene expression, but unlike lithium, VPA does not inhibit GSK-3β in vivo. VPA can inhibit GSK-3β-mediated phosphorylation of a CREB peptide in vitro. VPA may activate Wnt-dependent gene expression through inhibition of HDAC, which in turn leads to both increased expression of β-catenin and de-repression of Tcf/Lef (as well as activation of other HDAC-regulated genes). In vitro, VPA can stimulate glutamic acid decarboxylase, which is involved in GABA biosynthesis, and inhibit GABA transaminase, succinic semialdehyde dehydrogenase, and α-ketoglutarate dehydrogenase, enzymes involved in GABA degradation[1]. Valproic acid relieves HDAC-dependent transcriptional repression and causes hyperacetylation of histones in cultured cells and in vivo. VPA induces differentiation and/or apoptosis of carcinoma cells, PML-RAR-transformed hematopoietic progenitor cells and leukemic blasts from AML patients[2]. In addition to selectively inhibiting the catalytic activity of class I HDACs, VPA also induces proteasomal degradation of HDAC2[3].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 NGG4Z4VHfW6ldHnvckBie3OjeR?= NXjpOpBuOSCvTR?= MmP6TY5kemWjc3WgbY4heHKxdHXpckBlcXO3bH\p[IUhcXOxbXXyZZNmKGyndnXsJIlvKEiHS{K5N{Bk\WyuczDheEAyKG2PIHL5JIludXWwb3Lsc5Q> M4C4ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NU[2O|MzLz5zN{W2Olc{OjxxYU6=
HEK293 M4rkdWZ2dmO2aX;uJIF{e2G7 NYH0TpFyOSCvTR?= MnnqTY5kemWjc3WgbY4hT1KSN{igdJJwfGWrbjDs[ZZmdCCrbjDISWszQTNiY3XscJMh[XRiMTDtUUBjgSCrbX31co9jdG:2 Mnu3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3Nk[3N|IoRjF5NU[2O|MzRC:jPh?=
A549 NF7GOGRHfW6ldHnvckBie3OjeR?= MnO1NVUxKHWP NWjKZ5p7OjRiaILz MmnDTY5pcWKrdHnvckBw\iCqdX3hckBJTEGFIHnuJGE2PDliY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZT3IOEBi[2W2eXzheIlwdiCjdDCxOVAhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdB?= MkPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{OUS4OFQoRjF6Mkm0PFQ1RC:jPh?=
GM15850 M1;EWWZ2dmO2aX;uJIF{e2G7 NEfwPWw1ODBidV2= M1HDdVEzKGi{cx?= M3jjbmlvcGmkaYTpc44hd2ZiSFTBR{BqdiCqdX3hckBIVTF3OEWwJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKHSxdHHsJIFk\XS7bHH0[YQhcGm|dH;u[UBt\X[nbDDheEA1ODBidV2gZYZ1\XJiMUKgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> NUT3OGxyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5NlE{PjdpPkG2PVIyOzZ5PD;hQi=>
PC12 NVTLWXJXTnWwY4Tpc44h[XO|YYm= NEfMR20yKHWP MYCyOEBpenN? MnX4TY5lfWO2aX;uJI9nKGG3dH;wbIFogSCrbjDyZZQhe3SjYnzlJIlv\HWlaXLs[UBRSzF{IHPlcIx{KGW6cILld5NqdmdiQUWzWEBidHCqYT3zfY52[2ynaX6gZZN{\XO|ZXSgZZMhSTV|VDDhcJBp[S2|eX71Z4xmcW5iY3zlZZJidmOnIHH0JFEhfU1iYX\0[ZIhOjRiaILzJIJ6KGSnboPpeI9u\XS{aXOgZY5idHm|aYO= NHvm[YY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO5NVk1QSd-MUizPVE6PDl:L3G+
PC12 M{jEfGZ2dmO2aX;uJIF{e2G7 NIK2e|MyKHWP MXu5OkBpenN? MX;JcoR2[3Srb36gc4Yh[XW2b4DoZYd6KGmwIILheEB{fGGkbHWgbY5lfWOrYnzlJHBEOTJiY3XscJMh\XiycnXzd4lv\yCHR1\QMWhFWTd2IHHzd4V{e2WmIHHzJJNwdHWkbHWgSWdHWC2KRGG3OEBkdGWjcnHuZ4Uh[XRiMTD1UUBi\nSncjC5OkBpenNiYomg[IVve2m2b33leJJq[yCjbnHsfZNqew>? NHOzRWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO5NVk1QSd-MUizPVE6PDl:L3G+
SK-N-MC NV:2N|ZjTnWwY4Tpc44h[XO|YYm= NWjhNItlOSCvTR?= MVG0PEBpenN? M2nwfGlv\HWldHnvckBw\iCjdYTvdIhi\3liaX6gbJVu[W5iU1utUk1OSyClZXzsd{BmgHC{ZYPzbY5oKEWJRmCtTGRSPzRiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEWJRmCtTGRSPzRiYXfndoVo[XSrb36gZZQhOSC3TTDh[pRmeiB2ODDodpMh[nliZHXud4l1d22ndILpZ{BidmGueYPpdy=> MmK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh|OUG5OFkoRjF6M{mxPVQ6RC:jPh?=
HL60 M{fGVWZ2dmO2aX;uJIF{e2G7 M2nnfFEhdU1? MX:yOEBpenN? NX;oPXVHUW6qaXLpeIlwdiCxZjDISGFEKGmwIHj1cYFvKEiONkCgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm|dH;u[UBJOyCjY3X0fYxifGmxbjDheEAyKG2PIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4T0bY5oKG2ndHjv[C=> M4TWZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C0PFk3Lz5{NUOwOFg6PjxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
acetyl-H4; 

PubMed: 20025549     


Changes in histone acetylation after valproic acid (VPA) exposure. LS174T and HCT116 cells were exposed to varying concentrations of VPA for 16 hours. Cellular protein extracts were prepared, as described in Materials and Methods, and analyzed by immunoblot assay with antibody against acetylated histone H4 (acetyl-H4). β-actin was included as a control to show equivalent protein loading.

Acetyl-H3; 

PubMed: 30387821     


Chidamide and VPA promoted an increase in the levels of histone H3 acetylation in human MM cells (RPMI-8226 and U266). 

p-IKKα/β / IKKα/β / NF-κB p65 / IκBα; 

PubMed: 30387821     


(C) Effects of VPA (1 mM) on the expression levels of NF-κB pathway-associated proteins in U266 cells. (D) Effects of VPA (0.5 mM) on the expression levels of NF-κB pathway-associated proteins in RPMI8226 cells. IκBα, inhibitor of NF-κB; IKK, IκB kinase; NF-κB, nuclear factor-κB; p, phosphorylated; VPA, valproic acid.

20025549 30387821
Growth inhibition assay
Cell viability; 

PubMed: 28101176     


Inhibitory effect of various doses of VPA on CAL27 cell proliferation. CAL27 cells were treated with 0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 mm/l VPA for 24, 48, 72, 96 and 120 h, respectively, in vitro. Cell viability was determined using MTT assay and analyzed as the percentage of the absorbance value compared with control. *P<0.05 vs. 0.0 mmol/l; #P<0.05 vs. 0 h. Error bars represent the standard error of the mean. VPA, valproic acid.

28101176
体内研究 Valproic acid (VPA) increases the level of the inhibitory neurotransmitter γ-aminobutyric acid (GABA), with acute administration causing a 15-45% increase in GABA in the brains of rodents[1]. VPA also inhibits tumor growth and metastasis in animal experiments. It is a well-tolerated drug even during long-term treatment[2].

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

- 合并
  • Cell lines: Neuro2A cells
  • Concentrations: 0.5-5 mM
  • Incubation Time: 24 h
  • Method:

    Neuro2A cells are treated with VPA (0.5-5 mM) or with TSA (300 nm) for 24 h and then histones are isolated. Histone acetylation is assessed by immunoblotting with an antibody specific to acetylated histone H4.


    (Only for Reference)
动物实验:

[2]

- 合并
  • Animal Models: Rats
  • Dosages: 1.25 mM/kg
  • Administration: i.p.
    (Only for Reference)

溶解度 (25°C)

化学数据

分子量 144.21
密度 0.9 g/mL at 25 °C
化学式

C8H16O2

CAS号 99-66-1
储存条件 2年 -20°C 液体
别名 2-Propylvaleric Acid, Valproate

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04671589 Not yet recruiting Drug: Meropenem Injection Drug Toxicity Mabaret Al-Asafara Hospitals June 2021 Phase 4
NCT04384172 Recruiting Device: Tibial e-stim|Device: Genital e-stim Female Sexual Dysfunction|Spinal Cord Injuries University of Michigan|International Society for the Study of Women''s Sexual Health|The Craig H. Neilsen Foundation November 11 2020 Not Applicable
NCT03962829 Terminated Drug: mCPP|Drug: Placebo oral tablet Eating Behavior|Obesity University of Birmingham|University Hospital Birmingham February 1 2019 Not Applicable
NCT03681158 Completed Drug: sodium valproate Epilepsy Sanofi October 5 2018 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
免费分装抑制剂

HDAC Signaling Pathway Map

相关HDAC产品

Tags: 购买Valproic acid (VPA) | Valproic acid (VPA)供应商 | 采购Valproic acid (VPA) | Valproic acid (VPA)价格 | Valproic acid (VPA)生产 | 订购Valproic acid (VPA) | Valproic acid (VPA)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID